Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03980509 · ClinicalTrials.gov registry record · Phase 1

A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors

A Phase 1 study, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT03980509: Completed Phase 1 study, sponsored by Medical University of South Carolina.

NCT03980509 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03980509, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether oral administration of curcumin causes biological changes in primary tumors of breast cancer patients.

Primary Outcome

Change in tumor proliferation rate will be based on apoptosis (DNA fragmentation) and cell proliferation (Ki67) assays in biopsies pre and post treatment with curcumin

Interventions

  • DRUG Curcumin

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2020-01-29
Est. Completion 2023-03-24
Phase Phase 1

What the finished NCT03980509 record still lists

NCT03980509 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 1 intervention - of which Curcumin is the first listed.

NCT03980509 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03980509 about?

NCT03980509 is a clinical study titled "A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors". The purpose of this study is to determine whether oral administration of curcumin causes biological changes in primary tumors of breast cancer patients.

What is the current status of trial NCT03980509?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-01-29. Estimated completion is 2023-03-24.

What interventions are being tested in trial NCT03980509?

The interventions under investigation include: Curcumin (DRUG).

Who is sponsoring clinical trial NCT03980509?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03980509's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03980509, the US trial registry maintained by the National Library of Medicine. NCT03980509 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.